Ironwood Pharmaceuticals (IRWD) Operating Leases (2019 - 2026)

Ironwood Pharmaceuticals (IRWD) has 8 years of Operating Leases data on file, last reported at $9.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 21.2% year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2026 stood at $9.2 million (down 21.2% YoY), and the FY2025 full-year result was $9.9 million, down 19.78% from the prior year.
• Operating Leases fell to $9.2 million in Q1 2026, from $9.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $18.0 million in Q1 2022 to a low of $9.2 million in Q1 2026.
• A 5-year average of $13.9 million and a median of $14.0 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases fell 9.22% in 2022 and slipped 21.2% in 2026, its largest moves.
• Tracing IRWD's Operating Leases over 5 years: stood at $16.6 million in 2022, then fell by 12.39% to $14.5 million in 2023, then dropped by 15.4% to $12.3 million in 2024, then declined by 19.78% to $9.9 million in 2025, then slipped by 6.45% to $9.2 million in 2026.
• Business Quant data shows IRWD's Operating Leases at $9.2 million in Q1 2026, $9.9 million in Q4 2025, and $10.5 million in Q3 2025.